RNA medicines biotech ReNAgade Therapeutics has raised $300 million in a Series A financing round led by MPM BioImpact and F2 Ventures. ReNAgade has built a comprehensive and complementary platform that combines its proprietary delivery technologies, including novel lipid nanoparticles (LNPs), with a broad array of coding, editing, and gene insertion tools, in an all-RNA […]

Biogen and partner Eisai have announced that the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai’s Phase 3 Clarity AD clinical trial confirms the clinical benefit of Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease (AD). Additionally, the committee members confirmed the overall benefit-risk profile of Leqembi, the […]

At the opening of the BIO International Convention, Mayor Michelle Wu announced a new City workforce initiative to train and employ Boston residents in life sciences careers. With recent industry reports from the MassBio and MassBioEd highlighting continued job growth in the industry, Mayor Wu announced her goal to help 1,000 Boston residents get trained and hired into […]

At the BIO International Convention, Governor Maura Healey announced that her administration is launching a new strategy for connecting employers to skilled, diverse workers in Massachusetts called MassTalent which will serve as a one-stop front door for companies to access multiple talent pipelines in high-growth industries like the life sciences, clean energy and advanced manufacturing. To […]

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming cell and gene therapies, announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by Matrix Capital Management, and joined by a leading group of new and existing investors. ElevateBio’s syndicate now includes new […]

Novo Nordisk and Life Edit Therapeutics, Inc., an ElevateBio company focused on next-generation gene editing technologies and therapeutics, today announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advancing base editing capabilities, Novo Nordisk will leverage Life Edit’s suite of […]

Eli Lilly has announced positive results of its Phase 3 study, showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Based on these results, Lilly will proceed with global regulatory submissions as quickly as possible and anticipates making a submission to the FDA this quarter. Lilly will work with the FDA and […]

Cambridge-based Convergent Therapeutics has completed a $90 million Series A financing that will support development of a pipeline of novel radioantibodies, including its lead program with CONV01-α for the treatment of advanced prostate cancer. Convergent is a clinical-stage biotech focused on developing next-generation radiopharmaceutical therapies for prostate and other cancers. “While considerable progress has been made in […]

Sarepta Therapeutics has announced that the FDA Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of SRP-9001, a gene transfer therapy for treatment of patients with a form of Duchenne muscular dystrophy (DMD). The committee’s vote, while not binding, will be considered by the FDA when making its decision […]

Cambridge-based Seres Therapeutics and Nestlé Health Science have announced FDA approval of Vowst, an orally administered microbiota-based therapeutic to prevent recurrence of C. difficile Infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). Vowst was previously granted Breakthrough Therapy and Orphan Drug Designations by the FDA. Recurrent CDI represents significant unmet need and is a leading cause […]